OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine
Category: #health  By Mateen Dalal  Date: 2020-07-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

OSE Immunotherapeutics receives $228,000 to develop COVID-19 vaccine

The novel coronavirus outbreak has turned out to be one of the worst disasters the world has witnessed in recent times. At times like this, pharmaceutical companies worldwide have been putting their best foot forward to find the vaccine for COVID-19.

As per the latest news, France-based OSE Immunotherapeutics has reportedly announced that it has obtained an additional grant of up to USD 228,000 for the development of a prophylactic vaccine to treat the COVID-19.

Sources cite that the grant is a part of the USD 1.14 million ‘Metropolitan Fund’ which was created by Nantes Metropole for health innovations that can tackle the COVID-19 health crisis. The company is working actively on the development of the SARS-CoV-2 prophylactic vaccine. This research program seeks the development of a vaccine, which is based on a multi-epitope peptide approach and focuses on memory T cells.

The firm uses its expertise in the selection and optimization of peptides related to disease to increase the T lymphocyte's memory response against specific antigens using its established optimization technology for neo-epitopes.

OSE Immunotherapeutics’ research and development team screened a large number of peptides from the various proteins of SARS-CoV- 2, SARS-CoV and MERS-CoV with the help of a bioinformatics approach and algorithms for predicting immunogenicity of the virus Genome and has selected immunodominant epitopes from eight major proteins.

For the record, more than 10 million have been infected by COVID-19 while over half a million people lost their lives. While more than seven million COVID-19 patients have recovered so far, researchers worldwide are trying to scale the development and production of a potential COVID-19 as soon as possible. 

Meanwhile, Russian scientists have also claimed that they would roll out the first batch of vaccines by mid-August. Sources cite that a small amount of the COVID-19 vaccine would be available to patients in the middle of August, and private companies would start production of vaccines in September.

Source Credit - https://www.benzinga.com/pressreleases/20/07/g16645378/ose-immunotherapeutics-receives-200-000-from-nantes-metropole-to-develop-covepit-its-covid-19-prop

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Alphabet’s Google to face lawsuit from NLRB for violating labor laws
Alphabet’s Google to face lawsuit from NLRB for violating labor laws
By Mateen Dalal

In a recent turn of events, U.S. government body National Labor Relations Board (NLRB) has reportedly issued a complaint against American multinational technology company, Google LLC for unlawfully monitoring as well as questioning its workers and su...

Britain’s CMA to levy tougher competition rules on Google and Facebook
Britain’s CMA to levy tougher competition rules on Google and Facebook
By Mateen Dalal

Facebook and Google accounted for around 80% of the total 14 billion pounds spent on digital advertising in 2019. MOW has reportedly accused Google of modifying its Chromium developer tools and Chrome browser to get greater control over advertiser...

Amazon, U.S. Government team up to prevent sale of counterfeit goods
Amazon, U.S. Government team up to prevent sale of counterfeit goods
By Mateen Dalal

According to reliable sources, Washington-headquartered American multinational technology company, Amazon.com Inc has reportedly initiated a joint venture with the U.S. government’s counterfeit agency, the IPR Center (National Intellectual Prop...